Skip to main content

Zymeworks Inc.

For the period ended Mar 31, 2026. Filed May 7, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 7, 2026

ZYME$31.46+2.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows

(In thousands)

Three Months Ended March 31,
20262025
Cash flows from operating activities:
Net loss$(44,162)$(22,636)
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation of property and equipment963981
Amortization of intangible assets1761,617
Stock-based compensation expense6,9356,402
Amortization of operating lease right-of-use assets1,708707
Amortization of debt issuance costs26—
Non-cash interest expense related to sale of royalties2,040—
Deferred income tax recovery(2,200)(410)
Unrealized foreign exchange gain(331)(32)
Changes in operating assets and liabilities:
Accounts receivable(36)31,219
Prepaid expenses and other current assets(1,726)2,872
Accounts payable and accrued liabilities(7,750)(21,219)
Operating lease liabilities(1,005)(814)
Deferred revenue(340)(2,093)
Income taxes payable(16)(1)
Net cash provided used in operating activities(45,718)(3,407)
Cash flows from investing activities:
Purchases of marketable securities—(34,032)
Proceeds from marketable securities70,17546,552
Acquisition of property and equipment(216)(16)
Acquisition of intangible assets—(322)
Net cash provided by investing activities69,95912,182
Cash flows from financing activities:
Issuance of common stock on exercise of stock options8,717772
Issuance of common stock through employee stock purchase plan607544
Purchases of common stock for retirement(76,151)—
Proceeds from sale of future royalties250,000—
Payments for transaction costs related to sale of future royalties(4,387)—
Net cash provided by financing activities178,7861,316
Effect of exchange rate changes on cash and cash equivalents9810
Net change in cash and cash equivalents203,12510,101
Cash and cash equivalents, beginning of period41,15766,103
Cash and cash equivalents, end of period$244,282$76,204
Supplemental cash flow information:
Net cash paid during the period for income taxes$245$387
Supplemental disclosure of non-cash investing and financing items:
Leased assets obtained in exchange for operating lease liabilities—765
Issuance costs related to sale of future royalties not yet paid1,176—
Acquisition of property and equipment and intangible assets not yet paid10081
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.